Published in Eur J Nucl Med on January 01, 1999
From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med (2009) 12.92
Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 2.35
PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat (2008) 1.72
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52
Assessment of response to endocrine therapy using FDG PET/CT in metastatic breast cancer: a pilot study. Eur J Nucl Med Mol Imaging (2011) 1.50
A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res (2009) 1.24
Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging (2004) 1.11
Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med (2007) 1.10
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
Monitoring therapeutic efficacy in breast carcinomas. Eur Radiol (2006) 1.03
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med (2011) 1.02
Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors. Neoplasia (2000) 1.01
Imaging response to systemic therapy for bone metastases. Eur Radiol (2009) 0.99
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res (2011) 0.98
Role and cost effectiveness of PET/CT in management of patients with cancer. Yale J Biol Med (2010) 0.97
The 2010 Philip S. Portoghese Medicinal Chemistry Lectureship: addressing the "core issue" in the design of estrogen receptor ligands. J Med Chem (2011) 0.95
Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer. J Nucl Med (2012) 0.94
Translational molecular imaging for cancer. Cancer Imaging (2005) 0.93
Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med (2009) 0.93
Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist (2015) 0.92
Assessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione. J Nucl Med (2012) 0.92
FDG-PET in monitoring therapy of breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.91
PET/CT and breast cancer. Eur J Nucl Med Mol Imaging (2004) 0.90
Immuno-positron emission tomography in cancer models. Semin Nucl Med (2010) 0.88
Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. Nucl Med Biol (2008) 0.85
Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[¹⁸F]fluoro-17β-oestradiol PET. Eur J Nucl Med Mol Imaging (2010) 0.84
Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. Eur J Nucl Med Mol Imaging (2008) 0.84
Imaging progesterone receptor in breast tumors: synthesis and receptor binding affinity of fluoroalkyl-substituted analogues of tanaproget. J Med Chem (2010) 0.84
Microfluidics for positron emission tomography probe development. Mol Imaging (2010) 0.84
Targeted functional imaging in breast cancer. Eur J Nucl Med Mol Imaging (2007) 0.84
Synthesis of Clinical-Grade [(18)F]-Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor-Targeting Therapeutic Drug. Int J Mol Imaging (2013) 0.81
Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer (2014) 0.81
18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg (2003) 0.80
Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer. Eur J Nucl Med Mol Imaging (2007) 0.80
Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol (2014) 0.79
Use of positron emission tomography in anticancer drug development. Invest New Drugs (2003) 0.79
Quantitative hormone therapy follow-up in an ER+/ERαKD mouse tumor model using FDG and [11C]-methionine PET imaging. EJNMMI Res (2012) 0.78
Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med (2016) 0.77
Synthesis and biological evaluation of two agents for imaging estrogen receptor β by positron emission tomography: challenges in PET imaging of a low abundance target. Nucl Med Biol (2012) 0.76
Positron emission tomography (PET): expanding the horizons of oncology drug development. Invest New Drugs (2003) 0.76
CoMSIA and docking study of rhenium based estrogen receptor ligand analogs. Steroids (2007) 0.75
Early Metabolic Flare in Squamous Cell Carcinoma after Chemotherapy is a Marker of Treatment Sensitivity In Vitro. Nucl Med Mol Imaging (2010) 0.75
Oestrogen-related tumour phenotype: positron emission tomography characterisation with ¹⁸F-FDG and ¹⁸F-FES. Br J Radiol (2012) 0.75
Can FDG PET/CT monitor the response to hormonal therapy in breast cancer patients? Eur J Nucl Med Mol Imaging (2012) 0.75
Review: Receptor Targeted Nuclear Imaging of Breast Cancer. Int J Mol Sci (2017) 0.75
Rapid synthesis of [18F]fluoroestradiol: remarkable advantage of microwaving over conventional heating. J Labelled Comp Radiopharm (2014) 0.75
AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment. Cancer Res (2016) 0.75
Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design. Acad Radiol (2017) 0.75
Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell (2001) 4.78
Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A (1986) 4.51
Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem (2000) 3.34
Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol (1997) 3.25
Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem (2001) 3.24
A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol (1984) 3.11
Hormonal contraception, vitamin A deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet (1997) 2.88
Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg (2001) 2.40
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry (1997) 2.32
In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000) 2.30
Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol (2001) 2.20
A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys (2001) 2.15
FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR Am J Roentgenol (2000) 1.96
Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev (1999) 1.93
Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta. Endocrinology (1999) 1.93
Factors influencing cosmetic results after conservation therapy for breast cancer. Int J Radiat Oncol Biol Phys (1995) 1.88
Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanus toxoid. Clin Exp Immunol (1983) 1.88
Indium-111-labeled leukocytes for the localization of abscesses: preparation, analysis, tissue distribution, and comparison with gallium-67 citrate in dogs. J Lab Clin Med (1977) 1.87
Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med (1982) 1.85
A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol (1992) 1.84
The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site. Steroids (1997) 1.80
Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol (1997) 1.77
Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans. J Nucl Med (1990) 1.77
Functional consequences of posttranslational isomerization of Ser46 in a calcium channel toxin. Science (1994) 1.73
Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res (2000) 1.69
High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A (2000) 1.69
Photoaffinity labels for estrogen binding proteins of rat uterus. Biochemistry (1973) 1.67
Evidence that phospholipase A2 activity is required for Golgi complex and trans Golgi network membrane tubulation. Proc Natl Acad Sci U S A (1998) 1.65
Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol (2001) 1.64
Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med (1999) 1.62
Indium-LLL labeled platelets: studies on preparation and evaluation of in vitro and in vivo functions. Thromb Res (1976) 1.61
Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med (1993) 1.56
Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals. J Nucl Med (1983) 1.55
Breast cancer: PET imaging of estrogen receptors. Radiology (1988) 1.53
The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol (1998) 1.52
Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med (2001) 1.51
Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology (2000) 1.50
MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans. Neurology (1987) 1.49
Blood-brain barrier permeability of 11C-labeled alcohols and 15O-labeled water. Am J Physiol (1976) 1.48
In vivo comparison of copper blood-pool agents: potential radiopharmaceuticals for use with copper-62. J Nucl Med (1991) 1.46
Ventilation-perfusion studies in suspected pulmonary embolism. AJR Am J Roentgenol (1979) 1.45
Elevations of CK-MB following pulmonary embolism. A manifestation of occult right ventricular infarction. Chest (1992) 1.44
In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol (1990) 1.42
Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J Steroid Biochem (1982) 1.41
Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol (1997) 1.40
Estrogen and antiestrogen action in reproductive tissues and tumors. Recent Prog Horm Res (1979) 1.39
Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol (2001) 1.39
Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens. Chem Biol (1999) 1.39
Zearalenones: characterization of the estrogenic potencies and receptor interactions of a series of fungal beta-resorcylic acid lactones. Endocrinology (1979) 1.36
Preparation and evaluation of 111In-labeled leukocytes as an abscess imaging agent in dogs. Radiology (1976) 1.36
Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res (1996) 1.35
Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med (1995) 1.34
Diffusible Factors Essential for Epidermal Cell Redifferentiaion in Catharanthus roseus. Science (1989) 1.33
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg (1998) 1.30
Copper-64-labeled antibodies for PET imaging. J Nucl Med (1992) 1.29
Estrogen receptors: selective ligands, partners, and distinctive pharmacology. Recent Prog Horm Res (2000) 1.29
Homodimeric and heterodimeric bis(amino thiol) oxometal complexes with rhenium(V) and technetium(V). Control of heterodimeric complex formation and an approach to metal complexes that mimic steroid hormones. J Med Chem (1994) 1.29
Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum (2000) 1.25
Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med (2001) 1.25
Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology (1993) 1.24
Quantification of regional myocardial blood flow in vivo with H215O. Circulation (1984) 1.24
Efficient and highly selective covalent labeling of the estrogen receptor with [3H]tamoxifen aziridine. J Biol Chem (1983) 1.24
Vocal cord dysfunction in a child with asthma. J Asthma (1991) 1.23
RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med (1995) 1.21
Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med (1991) 1.21
Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Proc Natl Acad Sci U S A (1996) 1.20
Color Doppler US of the scrotum. Radiographics (1991) 1.20
Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg (1997) 1.18
Acute scrotal disorders: prospective comparison of color Doppler US and testicular scintigraphy. Radiology (1990) 1.18
Scintigraphic detection of atherosclerotic lesions and venous thrombi in man by indium-111-labelled autologous platelets. Lancet (1978) 1.17
The measure in vivo of regional cerebral oxygen utilization by means of oxyhemoglobin labeled with radioactive oxygen-15. J Clin Invest (1970) 1.17
Positron emission tomographic measurement of cerebral blood flow and permeability-surface area product of water using [15O]water and [11C]butanol. J Cereb Blood Flow Metab (1987) 1.16
Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2-deoxy-D-glucose. Radiology (1996) 1.16
High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol (1999) 1.15
Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. J Steroid Biochem Mol Biol (2000) 1.14
Progestin-rhenium complexes: metal-labeled steroids with high receptor binding affinity, potential receptor-directed agents for diagnostic imaging or therapy. Bioconjug Chem (1992) 1.13
Cerebrospinal fluid infusion test. Identification of artifacts and correlation with cisternography and pneumoencephalography. Neurology (1974) 1.13
Anti-estrogen interaction with uterine estrogen receptors. Studies with a radiolabeled anti-estrogen (CI-628). J Biol Chem (1978) 1.11
Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR Am J Roentgenol (1997) 1.11
Indium-111-labeled cellular blood components: mechanism of labeling and intracellular location in human neutrophils. J Nucl Med (1977) 1.10
Identification of cysteine 530 as the covalent attachment site of an affinity-labeling estrogen (ketononestrol aziridine) and antiestrogen (tamoxifen aziridine) in the human estrogen receptor. J Biol Chem (1989) 1.10
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release. Mol Endocrinol (2001) 1.10
NCA 16 alpha-[18F]fluoroestradiol-17 beta: the effect of reaction vessel on fluorine-18 resolubilization, product yield, and effective specific activity. Int J Rad Appl Instrum A (1986) 1.10